JP2015525230A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015525230A5 JP2015525230A5 JP2015517364A JP2015517364A JP2015525230A5 JP 2015525230 A5 JP2015525230 A5 JP 2015525230A5 JP 2015517364 A JP2015517364 A JP 2015517364A JP 2015517364 A JP2015517364 A JP 2015517364A JP 2015525230 A5 JP2015525230 A5 JP 2015525230A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- binding protein
- antibody
- optionally
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000025171 antigen binding proteins Human genes 0.000 claims 15
- 108091000831 antigen binding proteins Proteins 0.000 claims 15
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 206010028289 Muscle atrophy Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 210000003205 muscle Anatomy 0.000 claims 4
- 201000000585 muscular atrophy Diseases 0.000 claims 4
- 206010006895 Cachexia Diseases 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 3
- 238000000423 cell based assay Methods 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 101710194452 Growth/differentiation factor 11 Proteins 0.000 claims 2
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 claims 2
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims 2
- 108010056852 Myostatin Proteins 0.000 claims 2
- 108010023082 activin A Proteins 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 230000009977 dual effect Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims 2
- 230000037257 muscle growth Effects 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 102000018918 Activin Receptors Human genes 0.000 claims 1
- 108010052946 Activin Receptors Proteins 0.000 claims 1
- 206010002261 Androgen deficiency Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 208000037157 Azotemia Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 208000036119 Frailty Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000011623 Obstructive Lung disease Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000003042 antagnostic effect Effects 0.000 claims 1
- 206010003549 asthenia Diseases 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 102000023732 binding proteins Human genes 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000001076 sarcopenia Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 208000009852 uremia Diseases 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261658237P | 2012-06-11 | 2012-06-11 | |
| US61/658,237 | 2012-06-11 | ||
| PCT/US2013/045245 WO2013188448A2 (en) | 2012-06-11 | 2013-06-11 | Dual receptor antagonistic antigen-binding proteins and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015525230A JP2015525230A (ja) | 2015-09-03 |
| JP2015525230A5 true JP2015525230A5 (enExample) | 2016-08-04 |
Family
ID=49758865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015517364A Withdrawn JP2015525230A (ja) | 2012-06-11 | 2013-06-11 | デュアル受容体アンタゴニスト性抗原結合タンパク質およびその使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US9453080B2 (enExample) |
| EP (3) | EP2859114B1 (enExample) |
| JP (1) | JP2015525230A (enExample) |
| KR (1) | KR20150030706A (enExample) |
| CN (1) | CN104540961A (enExample) |
| AU (1) | AU2013274347B2 (enExample) |
| BR (1) | BR112014031028A2 (enExample) |
| CA (1) | CA2877669A1 (enExample) |
| CL (1) | CL2014003372A1 (enExample) |
| CO (1) | CO7240399A2 (enExample) |
| EA (1) | EA201492282A1 (enExample) |
| HK (1) | HK1208499A1 (enExample) |
| IL (1) | IL236133A0 (enExample) |
| MA (1) | MA37761A1 (enExample) |
| MX (1) | MX2014015195A (enExample) |
| NZ (1) | NZ703724A (enExample) |
| PE (1) | PE20150642A1 (enExample) |
| PH (1) | PH12014502754A1 (enExample) |
| SG (2) | SG11201408228QA (enExample) |
| TN (2) | TN2015000448A1 (enExample) |
| WO (1) | WO2013188448A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9453080B2 (en) | 2012-06-11 | 2016-09-27 | Amgen Inc. | Dual receptor antagonistic antigen-binding proteins and uses thereof |
| LT3835310T (lt) | 2012-09-13 | 2024-04-25 | Bristol-Myers Squibb Company | Fibronektino pagrindo karkaso domeno baltymai, kurie rišasi prie miostatino |
| JP2017538701A (ja) * | 2014-12-08 | 2017-12-28 | ノバルティス アーゲー | サルコペニアの治療のためのミオスタチンまたはアクチビンアンタゴニスト |
| GB201500464D0 (en) * | 2015-01-12 | 2015-02-25 | Crescendo Biolog Ltd | Method of producing optimised therapeutic molecules |
| CN109311998A (zh) * | 2016-02-22 | 2019-02-05 | 阿塞勒隆制药公司 | 用于增加免疫活性的ActRII拮抗剂 |
| KR102457751B1 (ko) | 2016-03-10 | 2022-10-21 | 악셀레론 파마 인코포레이티드 | 액티빈 타입 2 수용체 결합 단백질 및 이의 용도 |
| EP3538123A4 (en) | 2016-11-10 | 2020-10-14 | Keros Therapeutics, Inc. | ACTIVIN RECEPTOR TYPE IIA VARIANTS AND THEIR METHODS OF USE |
| JOP20190152A1 (ar) * | 2016-12-21 | 2019-06-20 | Novartis Ag | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة |
| EP3593144A1 (en) * | 2017-03-10 | 2020-01-15 | UCL Business Ltd | Method relating to myostatin pathway inhibition |
| WO2018183376A1 (en) * | 2017-03-28 | 2018-10-04 | Rigel Pharmaceuticals, Inc. | Acvr2a-specific antibody and method of use thereof |
| CA3082146A1 (en) | 2017-11-09 | 2019-05-16 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| CN120399032A (zh) | 2018-01-12 | 2025-08-01 | 科乐斯疗法公司 | 激活素受体iib型变体及其使用方法 |
| EP3790572A4 (en) | 2018-05-09 | 2022-03-16 | Keros Therapeutics, Inc. | ACTIVIN RECEPTOR TYPE IIA VARIANTS AND METHODS OF USE THEREOF |
| JP7669291B2 (ja) * | 2019-05-30 | 2025-04-28 | アクセレロン ファーマ インコーポレーテッド | Ａｃｔｒｉｉ結合性タンパク質及びその使用 |
| WO2021189006A1 (en) * | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iia variants |
| EP4121088A4 (en) * | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| CN116802298A (zh) * | 2021-01-13 | 2023-09-22 | 安斯泰来制药株式会社 | 与ActRIIA、ActRIIB和Fn14结合的多特异性抗体 |
| WO2025027052A1 (en) | 2023-07-31 | 2025-02-06 | Sixpeaks Bio Ag | Antibody conjugates and fusion proteins |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| DE3785186T2 (de) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ATE144793T1 (de) | 1989-06-29 | 1996-11-15 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| JPH06500011A (ja) | 1990-06-29 | 1994-01-06 | ラージ スケール バイオロジー コーポレイション | 形質転換された微生物によるメラニンの製造 |
| FR2664073A1 (fr) | 1990-06-29 | 1992-01-03 | Thomson Csf | Moyens de marquage d'objets, procede de realisation et dispositif de lecture. |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| JPH06506105A (ja) | 1990-08-29 | 1994-07-14 | ファーミング ビーブイ | 哺乳動物細胞における相同性組換え |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| WO1992022670A1 (en) | 1991-06-12 | 1992-12-23 | Genpharm International, Inc. | Early detection of transgenic embryos |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| DE69233204T2 (de) | 1991-12-13 | 2004-07-15 | Xoma Corp., Berkeley | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| JPH07508410A (ja) | 1992-06-18 | 1995-09-21 | ジェンファーム インターナショナル インコーポレイテッド | 酵母人工染色体を有するトランスジェニック非ヒト動物の製造方法 |
| US6066718A (en) | 1992-09-25 | 2000-05-23 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
| US5981175A (en) | 1993-01-07 | 1999-11-09 | Genpharm Internation, Inc. | Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
| US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
| US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| AU2001259432B2 (en) | 2000-05-03 | 2005-04-21 | Amgen Inc. | Modified peptides, comprising an FC domain, as therapeutic agents |
| ES2551852T3 (es) * | 2004-07-23 | 2015-11-24 | Acceleron Pharma Inc. | Polipéptidos del receptor ActRII |
| US20100120627A1 (en) * | 2006-08-02 | 2010-05-13 | Abdelmajid Belouchi | Genemap of the human genes associated with psoriasis |
| TWI573802B (zh) | 2007-03-06 | 2017-03-11 | 安美基公司 | 變異之活動素受體多肽及其用途 |
| ME02652B (me) | 2008-11-26 | 2017-06-20 | Amgen Inc | Stabilizovana varijanta aktivin iib receptora |
| NO2424895T3 (enExample) | 2009-04-27 | 2018-02-03 | ||
| US8524217B2 (en) | 2010-05-11 | 2013-09-03 | Merck Sharp & Dohme Corp. | MCP1-Ig fusion variants |
| JP6145112B2 (ja) | 2011-12-19 | 2017-06-07 | アムジエン・インコーポレーテツド | 単独でのまたは化学療法と組み合わされた変異アクチビン受容体ポリペプチド、およびその使用 |
| US9453080B2 (en) * | 2012-06-11 | 2016-09-27 | Amgen Inc. | Dual receptor antagonistic antigen-binding proteins and uses thereof |
| JP6071725B2 (ja) | 2013-04-23 | 2017-02-01 | カルソニックカンセイ株式会社 | 電気自動車の駆動力制御装置 |
-
2013
- 2013-06-11 US US14/407,421 patent/US9453080B2/en active Active
- 2013-06-11 CA CA2877669A patent/CA2877669A1/en not_active Abandoned
- 2013-06-11 MA MA37761A patent/MA37761A1/fr unknown
- 2013-06-11 WO PCT/US2013/045245 patent/WO2013188448A2/en not_active Ceased
- 2013-06-11 SG SG11201408228QA patent/SG11201408228QA/en unknown
- 2013-06-11 EP EP13804428.4A patent/EP2859114B1/en active Active
- 2013-06-11 SG SG10201610356YA patent/SG10201610356YA/en unknown
- 2013-06-11 MX MX2014015195A patent/MX2014015195A/es unknown
- 2013-06-11 EA EA201492282A patent/EA201492282A1/ru unknown
- 2013-06-11 CN CN201380042597.XA patent/CN104540961A/zh active Pending
- 2013-06-11 BR BR112014031028A patent/BR112014031028A2/pt not_active IP Right Cessation
- 2013-06-11 TN TN2015000448A patent/TN2015000448A1/en unknown
- 2013-06-11 HK HK15108981.7A patent/HK1208499A1/xx unknown
- 2013-06-11 KR KR1020157000579A patent/KR20150030706A/ko not_active Withdrawn
- 2013-06-11 EP EP18203126.0A patent/EP3498857A1/en active Pending
- 2013-06-11 AU AU2013274347A patent/AU2013274347B2/en not_active Expired - Fee Related
- 2013-06-11 PE PE2014002415A patent/PE20150642A1/es not_active Application Discontinuation
- 2013-06-11 JP JP2015517364A patent/JP2015525230A/ja not_active Withdrawn
- 2013-06-11 NZ NZ703724A patent/NZ703724A/en not_active IP Right Cessation
- 2013-06-11 EP EP19169804.2A patent/EP3540070A1/en active Pending
-
2014
- 2014-12-08 IL IL236133A patent/IL236133A0/en unknown
- 2014-12-09 PH PH12014502754A patent/PH12014502754A1/en unknown
- 2014-12-10 TN TN2014000513A patent/TN2014000513A1/fr unknown
- 2014-12-11 CL CL2014003372A patent/CL2014003372A1/es unknown
-
2015
- 2015-01-08 CO CO15003908A patent/CO7240399A2/es unknown
-
2016
- 2016-08-25 US US15/247,792 patent/US10266598B2/en active Active
-
2019
- 2019-03-05 US US16/293,254 patent/US10981999B2/en active Active
-
2021
- 2021-03-18 US US17/205,144 patent/US20210340262A1/en not_active Abandoned
-
2023
- 2023-10-19 US US18/381,745 patent/US20240327526A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015525230A5 (enExample) | ||
| EA201590138A1 (ru) | Оптимизация антител, которые связывают ген активации лимфоцитов 3 (lag-3), и их применение | |
| NO20210499A1 (no) | Humanisert, glykoomkonstruert Type II anti-CD20 antistoff og anvendelse derav, samt vertscelle og farmasøytisk sammensetning | |
| JP2016539096A5 (enExample) | ||
| JP2020503001A5 (enExample) | ||
| FI3736291T3 (fi) | Anti-fcrh5-vasta-aineita | |
| JP2014527814A5 (enExample) | ||
| JP2013538057A5 (enExample) | ||
| Venkataramani et al. | Design and characterization of Zweimab and Doppelmab, high affinity dual antagonistic anti-TSLP/IL13 bispecific antibodies | |
| JP2014526898A5 (enExample) | ||
| JP2017522888A5 (enExample) | ||
| JP2010524489A5 (enExample) | ||
| JP2020517635A5 (enExample) | ||
| WO2008017963A3 (en) | Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof | |
| JP2014503189A5 (enExample) | ||
| JP2012531922A5 (ja) | Ｔｏｌｌ様受容体２へのヒト化抗体またはその抗原結合部位 | |
| JP2012070740A5 (enExample) | ||
| JP2012525128A5 (enExample) | ||
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| EA201390278A1 (ru) | Антитела к ох40 и способы их применения | |
| JP2012518425A5 (enExample) | ||
| JP2015214563A5 (enExample) | ||
| BR112012018914A2 (pt) | "anticorpo humanizado, proteína de ligação de antígeno, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, proteína de ligação de anticorpo ou de antígeno, métodos para a produção de uma proteína de ligação de antígeno e para tratar um sujeito afetado por uma doença autoimune ou inflamatória, e, composição farmacêutica." | |
| WO2006082515A3 (en) | Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof | |
| JP2014158480A5 (enExample) |